These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9715839)

  • 41. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.
    Gardner LI; Harrison SH; Hendrix CW; Blatt SP; Wagner KF; Chung RC; Harris RW; Cohn DL; Burke DS; Mayers DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):345-53. PubMed ID: 9525436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients.
    Gallicano KD; Sahai J; Shukla VK; Seguin I; Pakuts A; Kwok D; Foster BC; Cameron DW
    Br J Clin Pharmacol; 1999 Aug; 48(2):168-79. PubMed ID: 10417493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zidovudine update: 1990.
    Morse GD; Lechner JL; Santora JA; Rozek SL
    DICP; 1990; 24(7-8):754-60. PubMed ID: 2197818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methadone and antiretroviral medications, part I.
    Gourevitch MN; Friedland GH
    AIDS Clin Care; 1999 Apr; 11(4):30-1 contd. PubMed ID: 11366210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?
    Briand N; Warszawski J; Mandelbrot L; Dollfus C; Pannier E; Cravello L; Nguyen R; Matheron I; Winer N; Tubiana R; Rouzioux C; Faye A; Blanche S;
    Clin Infect Dis; 2013 Sep; 57(6):903-14. PubMed ID: 23728147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.
    Stretcher BN; Pesce AJ; Frame PT; Stein DS
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1541-7. PubMed ID: 7979286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K; Dudley MN; Posner MR; Darnowski J
    Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.
    Hurwitz SJ; Asif G; Kivel NM; Schinazi RF
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4241-50. PubMed ID: 18838591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.
    Flynn PM; Rodman J; Lindsey JC; Robbins B; Capparelli E; Knapp KM; Rodriguez JF; McNamara J; Serchuck L; Heckman B; Martinez J;
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3516-22. PubMed ID: 17664328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers.
    Wattanagoon Y; Na Bangchang K; Hoggard PG; Khoo SH; Gibbons SE; Phiboonbhanakit D; Karbwang J; Back DJ
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1986-9. PubMed ID: 10858368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
    Rougemont M; Nchotu Ngang P; Stoll B; Delhumeau C; Hill A; Ciaffi L; Bonnet F; Menga G; Fampou JC; Calmy A
    HIV Med; 2016 Mar; 17(3):206-15. PubMed ID: 26354678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intestinal malabsorption and zidovudine bioavailability.
    Guarino A; Albano F; Castaldo A; Spagnuolo MI; Canani RB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 May; 18(1):91-2. PubMed ID: 9593465
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
    Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
    Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection.
    Morse GD; Olson J; Portmore A; Taylor C; Plank C; Reichman RC
    Antiviral Res; 1989 Mar; 11(2):57-65. PubMed ID: 2729955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
    Haubrich R; Thompson M; Schooley R; Lang W; Stein A; Sereni D; van der Ende ME; Antunes F; Richman D; Pagano G; Kahl L; Fetter A; Brown DJ; Clumeck N
    AIDS; 1999 Dec; 13(17):2411-20. PubMed ID: 10597783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.